The current Adderall shortage, first reported on Sept. 19, is due to both supply-side issues and a significant increase in demand during the pandemic.
Teva Pharmaceutical, the largest seller of Adderall in the U.S., has highlighted 'packing capacity constraints' and labor shortages as key factors worsening the shortage.
Doctors are often forced to explore alternative treatments due to the Adderall shortage, but patients face adjustment challenges and may experience unwanted side effects.
The biggest risk associated with the shortage is that untreated ADHD can lead to uncontrolled symptoms, affecting patients' concentration and their ability to perform daily activities.
#adderall-shortage #adhd-treatment #pharmaceutical-supply-chain #covid-19-impact #prescription-medication-issues
[
Collection
]
[
|
...
]